Joel R. Eisner

2.0k citations

42 papers · 1.5k indexed · 1 hit paper · h-index 17

Impact in

Reproductive Medicine top 1%
- Ovarian function and disorders
Public Health, Environmental and Occupational Health top 5%
- Reproductive Biology and Fertility
- Male Breast Health Studies

Papers in ⓘ

Cancer Research 12
- Cancer, Hypoxia, and Metabolism 5
Pulmonary and Respiratory Medicine 26
- Prostate Cancer Treatment and Research 22
- Advanced Breast Cancer Therapies 6

Co-authors: David H. Abbott (10 shared papers)Daniel A. Dumesic (7 shared papers)Joseph W. Kemnitz (4 shared papers)Ricki J. Colman (3 shared papers)Edwina Baskin-Bey (8 shared papers)Robert W. Goy (1 shared paper)Anthony Elias (4 shared papers)Ayca Gucalp (5 shared papers)
Journals: Journal of Clinical Oncology (14 papers)Fertility and Sterility (4 papers)Clinical Cancer Research (3 papers)Cancer Research (3 papers)British Journal of Cancer (2 papers)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Joel R. Eisner

41 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Male breast cancer: a disease distinct from female breast cancer 2018 · 230 citations

Peers

Countries citing papers authored by Joel R. Eisner

Since Specialization

Citations

This map shows the geographic impact of Joel R. Eisner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel R. Eisner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel R. Eisner more than expected).

Fields of papers citing papers by Joel R. Eisner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel R. Eisner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel R. Eisner. The network helps show where Joel R. Eisner may publish in the future.

Co-authors

The 25 scholars most cited alongside Joel R. Eisner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joel R. Eisner Line = papers co-authored together Joel R. Eisner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Male breast cancer: a disease distinct from female breast cancer Breast Cancer Research and Treatment ·Ayca Gucalp, Tiffany A. Traina, Joel R. Eisner, Joel S. Parker, Sara R. Selitsky, Ben Ho Park, Anthony Elias, Edwina Baskin-Bey, Fátima Cardoso Hit paper breakdown →	2018	230
2	Insights into the Development of Polycystic Ovary Syndrome (PCOS) from Studies of Prenatally Androgenized Female Rhesus Monkeys Trends in Endocrinology and Metabolism ·David H. Abbott, Daniel A. Dumesic, Joel R. Eisner, Ricki J. Colman, Joseph W. Kemnitz	1998	177
3	Timing of Prenatal Androgen Excess Determines Differential Impairment in Insulin Secretion and Action in Adult Female Rhesus Monkeys¹ The Journal of Clinical Endocrinology & Metabolism ·Joel R. Eisner, Daniel A. Dumesic, Joseph W. Kemnitz, David H. Abbott	2000	145
4	Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood Fertility and Sterility ·Daniel A. Dumesic, David H. Abbott, Joel R. Eisner, Robert W. Goy	1997	134
5	Increased Adiposity in Female Rhesus Monkeys Exposed to Androgen Excess During Early Gestation Obesity Research ·Joel R. Eisner, Daniel A. Dumesic, Joseph W. Kemnitz, Ricki J. Colman, David H. Abbott	2003	114
6	Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess Fertility and Sterility ·Joel R. Eisner, Melissa A. Barnett, Daniel A. Dumesic, David H. Abbott	2002	114
7	Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience British Journal of Cancer ·Tracy L. Rose, William H. Weir, Gregory M. Mayhew, Yoichiro Shibata, Patrick Eulitt, Joshua M. Uronis, Mi Zhou, Matthew E. Nielsen, Angela B. Smith, Michael Woods, Michele C. Hayward, Ashley H. Salazar, Matthew I. Milowsky, Sara E. Wobker, Katrina McGinty, Michael V. Millburn, Joel R. Eisner, William Y. Kim	2021	108
8	Insulin Resistance and Impaired Insulin Secretion in Prenatally Androgenized Male Rhesus Monkeys The Journal of Clinical Endocrinology & Metabolism ·Cristin M. Bruns, Scott T. Baum, Ricki J. Colman, Joel R. Eisner, Joseph W. Kemnitz, Richard Weindruch, David H. Abbott	2004	73
9	Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors Bioorganic & Medicinal Chemistry Letters ·Stephen W Rafferty, Joel R. Eisner, William R. Moore, Robert J. Schotzinger, William J. Hoekstra	2014	45
10	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer Journal of Clinical Investigation ·John D. Norris, Stephanie J. Ellison, Jennifer G. Baker, David B. Stagg, Suzanne E. Wardell, Sung Hee Park, Holly M. Alley, Robert Baldi, Alexander P. Yllanes, Kaitlyn J. Andreano, James P. Stice, Scott A. Lawrence, Joel R. Eisner, Douglas K. Price, William R. Moore, William D. Figg, Donald P. McDonnell	2017	38
11	Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women Fertility and Sterility ·Daniel A. Dumesic, David H. Abbott, Joel R. Eisner, Rebekah R. Herrmann, Judd E. Reed, Timothy J. Welch, Michael Dam Jensen	1998	37
12	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer Breast Cancer Research and Treatment ·Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly Blackwell, Lisa A. Carey, Joel R. Eisner, Edwina Baskin-Bey, Tiffany A. Traina	2018	35
13	Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer Molecular Cancer Therapeutics ·Jessica L. Christenson, Kathleen O’Neill, Michelle M. Williams, Nicole S. Spoelstra, Kenneth L. Jones, G. Devon Trahan, Jordan Reese, Elaina T. Van Patten, Anthony Elias, Joel R. Eisner, Jennifer K. Richer	2021	28
14	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells Frontiers in Endocrinology ·Anna R. Michmerhuizen, Benjamin C. Chandler, Eric Olsen, Kari Wilder-Romans, Leah Moubadder, Meilan Liu, Andrea M. Pesch, Amanda Zhang, Cassandra L. Ritter, Shannon Ward, Alyssa Santola, Shyam Nyati, James M. Rae, Daniel F. Hayes, Felix Y. Feng, Daniel E. Spratt, Daniel Wahl, Joel R. Eisner, Lori J. Pierce, Corey Speers	2020	26
15	Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer Hormones and Cancer ·Jessica L. Christenson, Jane B. Trepel, Haythem Ali, Sunmin Lee, Joel R. Eisner, Edwina Baskin-Bey, Anthony Elias, Jennifer K. Richer	2018	21
16	VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC). Journal of Clinical Oncology ·Joel R. Eisner, David H. Abbott, Ian M. Bird, Stephen W Rafferty, William R. Moore, Robert J. Schotzinger	2012	17
17	Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. Journal of Clinical Oncology ·Ayca Gucalp, Michael Danso, Anthony Elias, Aditya Bardia, Haythem Ali, David A. Potter, Nashat Gabrail, Barbara Haley, Hung T. Khong, Elizabeth C. Riley, Leigh Ervin, Joel R. Eisner, Edwina Baskin-Bey, William R. Moore, Tiffany A. Traina	2017	16
18	Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer Clinical Cancer Research ·Shilpa Gupta, Luke T. Nordquist, Mark T. Fleming, William R. Berry, Jingsong Zhang, Sharon L. Ervin, Joel R. Eisner, Edwina Baskin-Bey, Neal D. Shore	2018	14
19	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment Clinical Genitourinary Cancer ·Ravi A. Madan, Keith T. Schmidt, Fatima Karzai, Cody J. Peer, Lisa M. Cordes, Cindy H. Chau, Seth M. Steinberg, Helen Owens, Joel R. Eisner, William R. Moore, William L. Dahut, James L. Gulley, William D. Figg	2020	14
20	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC. Journal of Clinical Oncology ·Johann S. de Bono, Carmel Pezaro, Silke Gillessen, Neal D. Shore, Luke T. Nordquist, Eleni Efstathiou, John C. Araujo, William R. Berry, Glenn Liu, Nicholas J. Vogelzang, Aurelius Omlin, Robert J. Schotzinger, Joel R. Eisner, William R. Moore	2015	9

About Joel R. Eisner

Joel R. Eisner is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Reproductive Medicine, Endocrinology, Diabetes and Metabolism and Genetics, having authored 42 papers that have together received 1.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (22 papers), Estrogen and related hormone effects (11 papers), Hormonal and reproductive studies (9 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Sexual Differentiation and Disorders (6 papers), Advanced Breast Cancer Therapies (6 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Ovarian function and disorders (5 papers). The work is most often cited by research in Reproductive Medicine (608 citations), Public Health, Environmental and Occupational Health (576 citations), Endocrinology, Diabetes and Metabolism (228 citations), Cancer Research (172 citations) and Pediatrics, Perinatology and Child Health (213 citations). Joel R. Eisner has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include David H. Abbott, Daniel A. Dumesic, Joseph W. Kemnitz, Ricki J. Colman, Edwina Baskin-Bey, Robert W. Goy, Anthony Elias, Ayca Gucalp, Tiffany A. Traina and Melissa A. Barnett. Their work appears in journals such as Journal of Clinical Oncology, Fertility and Sterility, Clinical Cancer Research, Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact